Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2004 1
2005 2
2006 1
2007 2
2008 3
2009 5
2010 1
2011 6
2012 2
2013 8
2014 3
2015 3
2016 5
2018 10
2019 10
2020 6
2021 10
2022 10
2023 7
2024 4

Text availability

Article attribute

Article type

Publication date

Search Results

87 results

Results by year

Filters applied: . Clear all
Page 1
TNIK inhibition sensitizes TNIK-overexpressing lung squamous cell carcinoma to radiotherapy.
Nguyen T, Carrieri FA, Connis N, Lafargue A, Chang J, Chan A, Shetty AC, Song Y, Hoang T, Jagtap S, Chowdhury DD, Khan MA, Gabrielson KL, Rezaee M, Torres-Ayuso P, Brognard J, Hann CL, Tran PT. Nguyen T, et al. Among authors: hann cl. Mol Cancer Ther. 2024 Apr 27. doi: 10.1158/1535-7163.MCT-23-0412. Online ahead of print. Mol Cancer Ther. 2024. PMID: 38670554
Impact of Tumor-intrinsic Molecular Features on Survival and Acquired Tyrosine Kinase Inhibitor Resistance in ALK-positive NSCLC.
Nakazawa M, Harada G, Ghanem P, Bubie A, Kiedrowski LA, Murray JC, Marrone KA, Scott SC, Houseknecht S, Falcon CJ, Evans P, Feliciano J, Hann CL, Ettinger DS, Smith KN, Anagnostou V, Forde PM, Brahmer JR, Levy B, Drilon A, Lam VK. Nakazawa M, et al. Among authors: hann cl. Cancer Res Commun. 2024 Mar 14;4(3):786-795. doi: 10.1158/2767-9764.CRC-24-0065. Cancer Res Commun. 2024. PMID: 38407352 Free PMC article.
Elucidating the Heterogeneity of Immunotherapy Response and Immune-Related Toxicities by Longitudinal ctDNA and Immune Cell Compartment Tracking in Lung Cancer.
Murray JC, Sivapalan L, Hummelink K, Balan A, White JR, Niknafs N, Rhymee L, Pereira G, Rao N, Weksler B, Bahary N, Phallen J, Leal A, Bartlett DL, Marrone KA, Naidoo J, Goel A, Levy B, Rosner S, Hann CL, Scott SC, Feliciano J, Lam VK, Ettinger DS, Li QK, Illei PB, Monkhorst K, Scharpf RB, Brahmer JR, Velculescu VE, Zaidi AH, Forde PM, Anagnostou V. Murray JC, et al. Among authors: hann cl. Clin Cancer Res. 2024 Jan 17;30(2):389-403. doi: 10.1158/1078-0432.CCR-23-1469. Clin Cancer Res. 2024. PMID: 37939140 Free PMC article.
Elucidating the heterogeneity of immunotherapy response and immune-related toxicities by longitudinal ctDNA and immune cell compartment tracking in lung cancer.
Murray JC, Sivapalan L, Hummelink K, Balan A, White JR, Niknafs N, Rhymee L, Pereira G, Rao N, Phallen J, Leal A, Bartlett DL, Marrone KA, Naidoo J, Levy B, Rosner S, Hann CL, Scott SC, Feliciano J, Lam VK, Ettinger DS, Li QK, Illei PB, Monkhorst K, Zaidi AH, Scharpf RB, Brahmer JR, Velculescu VE, Forde PM, Anagnostou V. Murray JC, et al. Among authors: hann cl. bioRxiv [Preprint]. 2023 Jun 26:2023.06.23.546338. doi: 10.1101/2023.06.23.546338. bioRxiv. 2023. PMID: 37425893 Free PMC article. Updated. Preprint.
Dynamics of Sequence and Structural Cell-Free DNA Landscapes in Small-Cell Lung Cancer.
Sivapalan L, Iams WT, Belcaid Z, Scott SC, Niknafs N, Balan A, White JR, Kopparapu P, Cann C, Landon BV, Pereira G, Velculescu VE, Hann CL, Lovly CM, Anagnostou V. Sivapalan L, et al. Among authors: hann cl. Clin Cancer Res. 2023 Jun 13;29(12):2310-2323. doi: 10.1158/1078-0432.CCR-22-2242. Clin Cancer Res. 2023. PMID: 37071497 Free PMC article.
Griseofulvin Radiosensitizes Non-Small Cell Lung Cancer Cells and Activates cGAS.
Wang X, Raman N, Lemtiri-Chlieh G, Chang J, Jagtap S, Chowdhury DD, Ballew M, Carrieri FA, Nguyen T, Nugent K, Peck T, Levine MS, Chan A, Lam C, Malek R, Hoang T, Phillips R, Cheng Z, Taparra K, Connis N, Hann CL, Holland A, Tran PT, Lafargue A, Wang H. Wang X, et al. Among authors: hann cl. Mol Cancer Ther. 2023 Apr 3;22(4):519-528. doi: 10.1158/1535-7163.MCT-22-0191. Mol Cancer Ther. 2023. PMID: 36752776 Free PMC article.
Persistent mutation burden drives sustained anti-tumor immune responses.
Niknafs N, Balan A, Cherry C, Hummelink K, Monkhorst K, Shao XM, Belcaid Z, Marrone KA, Murray J, Smith KN, Levy B, Feliciano J, Hann CL, Lam V, Pardoll DM, Karchin R, Seiwert TY, Brahmer JR, Forde PM, Velculescu VE, Anagnostou V. Niknafs N, et al. Among authors: hann cl. Nat Med. 2023 Feb;29(2):440-449. doi: 10.1038/s41591-022-02163-w. Epub 2023 Jan 26. Nat Med. 2023. PMID: 36702947 Free PMC article.
87 results